Brief: Nanjing Leads Biolabs Signs Exclusive Global License Agreement With Dianthus
16/10/2025 15:15
Oct 16 (Reuters) - Nanjing Leads Biolabs Co Ltd 9887.HK: EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH DIANTHUS FOR LBL-047 WILL RECEIVE UPFRONT AND POTENTIAL NEAR-TERM MILESTONE PAYMENTS UP TO $38 MILLION, UP TO $1 BILLION IN POTENTIAL CLINICAL DEVELOPMENT Further company coverage: 9887.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nanjing Leads Biolabs
See all newsBrief: Nanjing Leads Biolabs Says FDA Grants Fast Track Designation To LBL-024
Brief: Nanjing Leads Biolabs Posts HY Loss Attributable RMB221.9 Million
Nanjing Leads rises on clinical study progress on cancer treatment drug
Nanjing Leads Biolabs jumps on progress of tumor antibody treatment
Nanjing Leads Biolabs rises on NMPA's IND approval for colorectal cancer